vs
Side-by-side financial comparison of OneStream, Inc. (OS) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $163.7M, roughly 1.1× OneStream, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs 0.6%, a 1.0% gap on every dollar of revenue. On growth, OneStream, Inc. posted the faster year-over-year revenue change (23.6% vs 5.0%). Over the past eight quarters, OneStream, Inc.'s revenue compounded faster (21.8% CAGR vs -0.2%).
Blue Stream provides cable television, cable telephone, DVR, and up to 1 GIG Internet speed broadband services to customers in the Florida communities of Coral Springs and Weston.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
OS vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $163.7M | $177.4M |
| Net Profit | $999.0K | $2.9M |
| Gross Margin | 69.8% | — |
| Operating Margin | -3.2% | 3.9% |
| Net Margin | 0.6% | 1.6% |
| Revenue YoY | 23.6% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $163.7M | $196.9M | ||
| Q3 25 | $154.3M | $179.5M | ||
| Q2 25 | $147.6M | $181.1M | ||
| Q1 25 | $136.3M | $168.9M | ||
| Q4 24 | $132.5M | $187.3M | ||
| Q3 24 | $129.1M | $168.6M | ||
| Q2 24 | $117.5M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $999.0K | — | ||
| Q3 25 | $-8.8M | $5.4M | ||
| Q2 25 | $-18.4M | $-4.8M | ||
| Q1 25 | $-24.0M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-171.9M | $-143.5M | ||
| Q2 24 | $-7.8M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 69.8% | 79.5% | ||
| Q3 25 | 68.1% | 80.9% | ||
| Q2 25 | 68.6% | 77.4% | ||
| Q1 25 | 68.0% | 79.7% | ||
| Q4 24 | 66.8% | 78.7% | ||
| Q3 24 | 50.1% | 76.9% | ||
| Q2 24 | 68.5% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -3.2% | 1.2% | ||
| Q3 25 | -11.3% | 3.5% | ||
| Q2 25 | -21.8% | 4.7% | ||
| Q1 25 | -29.3% | 1.2% | ||
| Q4 24 | -35.8% | 13.2% | ||
| Q3 24 | -197.6% | -82.8% | ||
| Q2 24 | -9.8% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | -5.7% | 3.0% | ||
| Q2 25 | -12.5% | -2.7% | ||
| Q1 25 | -17.6% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -133.1% | -85.1% | ||
| Q2 24 | -6.7% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | $-1.06 | $-3.11 | ||
| Q2 24 | — | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $693.6M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $504.7M | $653.9M |
| Total Assets | $1.0B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $693.6M | $238.4M | ||
| Q3 25 | $653.9M | $246.3M | ||
| Q2 25 | $652.1M | $445.9M | ||
| Q1 25 | $593.9M | $493.6M | ||
| Q4 24 | $544.2M | $484.6M | ||
| Q3 24 | $495.5M | $453.8M | ||
| Q2 24 | $140.5M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $504.7M | $693.1M | ||
| Q3 25 | $472.1M | $727.2M | ||
| Q2 25 | $458.2M | $757.8M | ||
| Q1 25 | $412.9M | $798.5M | ||
| Q4 24 | $386.2M | $778.3M | ||
| Q3 24 | $458.2M | $749.6M | ||
| Q2 24 | $97.5M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.0B | $1.3B | ||
| Q3 25 | $949.4M | $1.3B | ||
| Q2 25 | $910.5M | $1.5B | ||
| Q1 25 | $867.3M | $1.6B | ||
| Q4 24 | $823.2M | $1.6B | ||
| Q3 24 | $750.1M | $1.5B | ||
| Q2 24 | $379.7M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $25.8M | — |
| Free Cash FlowOCF − Capex | $25.6M | — |
| FCF MarginFCF / Revenue | 15.7% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 25.79× | — |
| TTM Free Cash FlowTrailing 4 quarters | $95.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $25.8M | $43.7M | ||
| Q3 25 | $5.0M | $60.8M | ||
| Q2 25 | $29.7M | $12.0M | ||
| Q1 25 | $36.2M | $35.5M | ||
| Q4 24 | — | $33.1M | ||
| Q3 24 | $2.4M | $53.9M | ||
| Q2 24 | $8.1M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $25.6M | $43.5M | ||
| Q3 25 | $4.8M | $57.0M | ||
| Q2 25 | $29.4M | $9.3M | ||
| Q1 25 | $35.8M | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | $1.3M | $49.8M | ||
| Q2 24 | $7.7M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 15.7% | 22.1% | ||
| Q3 25 | 3.1% | 31.7% | ||
| Q2 25 | 19.9% | 5.1% | ||
| Q1 25 | 26.3% | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | 1.0% | 29.6% | ||
| Q2 24 | 6.6% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.1% | 2.2% | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | 0.3% | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | 0.8% | 2.4% | ||
| Q2 24 | 0.3% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 25.79× | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OS
| Subscription And Circulation | $150.3M | 92% |
| Professional Services And Other | $9.4M | 6% |
| License | $4.0M | 2% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
